

Disclosures

Personal Commercial (26)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Regent	Research/Research Grants ‡ HEART FID	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amgen Inc.	Research/Research Grants ‡ CardioHealth Alliance	None (\$0)	General Cardiology
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca	Research/Research Grants ‡ EXSCEL	Significant (>= \$5,000)	General Cardiology
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bayer Corporation US	Consultant Fees/Honoraria	Modest (< \$5,000)	
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ CardioHealth Alliance	None (\$0)	General Cardiology
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants ‡ EMPACT-MI; CardioHealth Alliance	Modest (< \$5,000)	Acute Coronary Syndromes
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Other - BMS acquired Myokardia and consulting via Myokardia	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eidos	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Research/Research Grants ‡ EMPACT-MI; Partnered with Boehringer Ingelheim a	None (\$0)	Heart Failure and Cardiomyopathies
Intellia	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
Intercept Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	Other
Merck & Co., Inc.	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Novo Nordisk Inc.	Research/Research Grants ‡ CardioHealth Alliance	None (\$0)	General Cardiology
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Prolalio	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Verily	Research/Research Grants	Significant (>= \$5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
American Heart Association	Other	None (\$0)	Heart Failure and Cardiomyopathies
National Institutes of Health	Research/Research Grants ‡ NIH Collaboratory, NHLBI Heart Failure Network	None (\$0)	General Cardiology Heart Failure and Cardiomyopathies Other
PCORI	Research/Research Grants ‡ PCORnet	None (\$0)	Other

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/9/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.